

Executive Summary / Investment Rationale

Nevia Bio is a liquid biopsy diagnostics company leveraging vaginal fluid to detect gynecological cancers earlier than blood-based methods. The gynecological cancer diagnostic market exceeds \$26B today and expected to grow to \$48B in 2032. Our first indication is focused on Ovarian cancer patients. Ovarian cancer is an aggressive and lethal cancer that can be treated if diagnosed at early stages, but unfortunately 75% of patients are diagnosed at late stages, when survival rates plummet from 90% to 20%. The company has demonstrated biomarker feasibility, secured strategic KOL relationships, and is led by an experienced team with a proven record developing and commercializing diagnostic products.

Core Technology

Nevia Bio's platform uniquely leverages vaginal fluid—a proximal and untapped biofluid—for early detection of gynecologic cancers. Combined with our proprietary immunoproteomics approach, targeting host immune response markers, we have the potential to diagnose patients with Ovarian cancer much earlier and more accurately than other liquid biopsy methods targeting biomarkers, such as circulating tumor DNA (ctDNA) in the bloodstream. This creates a novel diagnostic category with both clinical and commercial differentiation.

Product Profile / Pipeline

Lead product: early detection of ovarian cancer in adnexal mass patients, progressing to BRCA carriers and eventually to all women over 50 yrs old. A parallel RUO service for biopharma offers near-term revenue. Future pipeline includes endometrial and cervical cancer, as well as other gynecological conditions. Clinical evidence, regulatory and reimbursement pathways, and key partnerships will drive value inflection.

Business Strategy

Nevia Bio will pursue a dual-track model: RUO services to biopharma partners and development of a diagnostic assay (first as a CLIA LDT and ultimately as an FDA-cleared IVD). RUO will fund operations and provide clinical insight; the IVD will unlock reimbursement and scale. Partnerships with CLIA labs and distributors will accelerate adoption without a heavy commercial footprint.

What's Next?

We are finalizing a local validation study to support our scientific evidence and will leverage that to launch a service lab to conduct RUO services next year. In addition, we are ramping up towards an FDA clinical study next year. Financial plan targets seed extension or Series A to fund our pivotal trial, set up an R&D

and a CLIA lab, and U.S. market entry. Strategic alignment with reimbursement, regulatory, and commercial milestones.